Docetaxel-bevacizumab
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Docetaxel-bevacizumab, covering 2018-02-14 to 2018-02-14. Get the full timeline:
Most recent: Clinical Trial Update: Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer [Phase 2, Phase 3]